- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03611686
Observatory of Patients With Metastatic ProstAte Adenocarcinoma That is Resistant to Castration and Multi-LinE Strategies (OPALE)
November 5, 2019 updated by: University Hospital, Rouen
Evaluation the overall survival of patients with metastatic prostate adenocarcinoma resistant to castration
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Anticipated)
500
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Sophie GOUERANT, MD
- Phone Number: 8265 +3323288
- Email: sophie.gouerant@chu-rouen.fr
Study Locations
-
-
-
Rouen, France
- Recruiting
- ROUEN university hospital
-
Contact:
- Sophie GOUERANT, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Sampling Method
Non-Probability Sample
Study Population
Patients with metastatic prostate adenocarcinoma resistant to castration
Description
Inclusion Criteria:
- Patient monitored for castration-resistant metastatic prostate
- Patients starting a first or second line treatment as part of castration resistance
- Patient not objecting to the study after reading the information letter
- Patient aged over 18 years
Exclusion Criteria:
- Patient monitored for non-metastatic prostate cancer
- Patient monitored for castration-nonresistant prostate cancer
- Patient not able to understand the information letter
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
patient followed for metastatic prostate adenocarcinoma
patient wil be followed for metastatic prostate adenocarcinoma during 3 years
|
Local chemotherapy will be administrated according to local recommendation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of alive patient
Time Frame: 3 years
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of alive patient disease free
Time Frame: 3 years
|
3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Sophie GOUERANT, ROUEN university hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 17, 2018
Primary Completion (Anticipated)
April 1, 2026
Study Completion (Anticipated)
April 1, 2026
Study Registration Dates
First Submitted
July 26, 2018
First Submitted That Met QC Criteria
July 26, 2018
First Posted (Actual)
August 2, 2018
Study Record Updates
Last Update Posted (Actual)
November 6, 2019
Last Update Submitted That Met QC Criteria
November 5, 2019
Last Verified
November 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017/090/HP
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Prostate Adenocarcinoma
-
Imperial College LondonWellcome Trust; Imperial Clinical Trials Unit (ICTU)CompletedProstate Cancer | Metastatic Prostate Cancer | Prostate Adenocarcinoma | Prostate Cancer Metastatic | Metastatic Prostate Carcinoma in the Soft Tissue | Non-metastatic Prostate CancerUnited Kingdom
-
Sir Mortimer B. Davis - Jewish General HospitalTerminatedProstatic Neoplasms | Prostate Cancer | Metastatic Prostate Cancer | Prostate Adenocarcinoma | Metastatic Prostatic Adenocarcinoma | Metastatic Prostate Carcinoma in the Soft TissueCanada
-
National Cancer Institute (NCI)Active, not recruitingCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Adenocarcinoma AJCC v7 | Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation | Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation | Prostate Adenocarcinoma With Neuroendocrine...United States
-
OHSU Knight Cancer InstituteAstellas Pharma US, Inc.; Oregon Health and Science UniversityActive, not recruitingCastration-Resistant Prostate Carcinoma | Metastatic Malignant Neoplasm in the Bone | Metastatic Malignant Neoplasm in the Soft Tissues | Recurrent Prostate Carcinoma | Metastatic Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma AJCC v7 | Stage IV Prostate Adenocarcinoma AJCC v7United States
-
The University of Texas Health Science Center at...WithdrawnMetastatic Prostate Cancer | Prostate Cancer Metastatic | Metastatic Prostate Adenocarcinoma | Castrate Resistant Prostate CancerUnited States
-
Memorial Sloan Kettering Cancer CenterProgenics Pharmaceuticals, Inc.RecruitingProstate Cancer | Metastatic Prostate Cancer | Prostate Adenocarcinoma | Prostate Cancer Metastatic | Prostate NeoplasmUnited States
-
Beth Israel Deaconess Medical CenterDana-Farber Cancer Institute; Puma Biotechnology, Inc.WithdrawnProstate Cancer | Castration-resistant Prostate Cancer | Prostate Cancer Metastatic | Metastatic Prostate AdenocarcinomaUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyCompletedMetastatic Prostate Carcinoma | Metastatic Prostatic Adenocarcinoma | Prostate Carcinoma Metastatic to the BoneUnited States
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI); The Wayne D. Kuni and Joan E. Kuni FoundationTerminatedProstate Adenocarcinoma | Recurrent Prostate Carcinoma | Metastatic Prostatic Adenocarcinoma | Hormone-Resistant Prostate CancerUnited States
-
Weill Medical College of Cornell UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedMetastatic Prostate AdenocarcinomaUnited States
Clinical Trials on Local chemotherapy
-
M.D. Anderson Cancer CenterActive, not recruiting
-
Institut CurieZionexaRecruiting
-
Institut CurieFondation Rothschild ParisActive, not recruitingChildren | Retinoblastoma | Retinal NeoplasmFrance
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedOvarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity CancerUnited States
-
Institut CurieFondation Rothschild ParisRecruiting
-
Fujian Cancer HospitalZhejiang Cancer Hospital; Jiangxi Provincial Cancer HospitalNot yet recruitingNasopharyngeal CarcinomaChina
-
University of WashingtonNational Cancer Institute (NCI)CompletedAdult Acute Myeloid Leukemia | Adult Myelodysplastic SyndromeUnited States
-
Cancer Institute and Hospital, Chinese Academy...Unknown
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingColorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Colorectal Carcinoma Metastatic in the LungUnited States, Canada
-
Jing Jin, M.D.Recruiting